The global market for anticoagulants treating cancer-associated thrombosis is growing steadily. Valued at around billion in 2 ...

Revumenib is now the sole targeted therapy recommended by the National Comprehensive Cancer Network for KMT2A-rearranged acute leukemia, which opens a path for payers, said Ivo Abraham, PhD, RN, of ...